US4324779A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treating hypertonia with N-(2-furfuryl)-4-chloro-5-sulfamoyl-anthranilic acid and preparations thereof
Assignee: Sanofi Aventis Deutschland GmbH
•
Filing: 1979-09-20
•
Granted: 1982-04-13
•
Expires: 1999-09-20
Abstract
Abstract A method for treating hypertonia with a preparation of N-(2-furfuryl)-4-chloro-5-sulfamoyl-anthranilic acid having a slightly retarded release, wherein the release of the active substance in vitro, measured in the flow through-cell to Dibbern, is not more than 5% after 1 hour in a buffer solution of pH 1.5 and about 10 to at most 25% of the active substance content after a two-hour treatment in a buffer solution of pH 5.5.
Inventors
- 👤 Gebhard Dahlhausen
- 👤 Hans-Werner Dibbern
- 👤 Fulberth
- 👤 Gerhard Ross
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 04:12
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K31/00; A61K31/63; A61K31/635; A61K9/14; A61K9/16; A61K9/1605; A61K9/1617; A61K9/1682; A61K9/1688; A61K9/48; A61K9/50; A61K9/5073; A61K9/5078
Claims Analysis
Total Claims: 2
Claim 1
Independent Claim
136 words
A furosemide-containing pellet for the oral administration of furosemide, said pellet consisting essentially of a core of furosemide having thereover a sustained-release coating which starts to dissolve in a weakly acid medium, which coating, when its release characteristics are measured in vitro in a flow-through-cell according to Dibbern, (a) releases not more than 5 percent of said furosemide into a buffer solution having a pH of 1.5 during the first hour of measurement in said cell; (b) releases about 10 to at most 25 percent of said furosemide into a buffer solution having a pH of 5.5 during the second hour of measurement in said cell; and (c) releases the remainder of said furosemide substantially completely into a buffer solution having a pH of 7.5 during the third and fourth hours of measurement in said cell.
Claim 2
Dependent Claim
136 words
A furosemide-containing pellet for the oral administration of furosemide, said pellet consisting essentially of a core of furosemide having thereover a sustained-release coating which starts to dissolve in a weakly acid medium, which coating, when its release characteristics are measured in vitro in a flow-through-cell according to Dibbern, (a) releases not more than 5 percent of said furosemide into a buffer solution having a pH of 1.5 during the first hour of measurement in said cell; (b) releases about 10 to at most 25 percent of said furosemide into a buffer solution having a pH of 5.5 during the second hour of measurement in said cell; and (c) releases the remainder of said furosemide substantially completely into a buffer solution having a pH of 7.5 during the third and fourth hours of measurement in said cell.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-04-12 | 1985-10-12 | 1986-04-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-04-12 | 1989-10-12 | 1990-04-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-04-12 | 1993-10-12 | 1994-04-13 | $7700.00 | Window Closed / Lapsed |